Telaprevir for Retreatment of HCV Infection: Review of the REALIZE Trial

• Di Bisceglie AM , LyraAC, SchwartzM et al. Hepatitis C-related hepatocellular carcinoma in the United States: influence of ethnic status. Am. J. Gastroenterol. 98 , 2060–2063 (2003).
   PubMed Web of Science ®Google Scholar
• Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. J. Viral. Hepat.6 , 35–47 (1999).
   PubMed Web of Science ®Google Scholar
• Jou JH , MuirAJ. In the clinic. Hepatitis C. Ann. Intern. Med.148 , ITC6-1–ITC6-16 (2008).
   Web of Science ®Google Scholar
• Swain MG , LaiMY, ShiffmanML et al. A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin. Gastroenterology 139 , 1593–1601 (2010).
   PubMed Web of Science ®Google Scholar
• Ghany MG , StraderDB, ThomasDL, SeeffLB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology49 , 1335–1374 (2009).
   PubMed Web of Science ®Google Scholar
• Ghany MG , NelsonDR, StraderDB, ThomasDL, SeeffLB. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology54 , 1433–1444 (2011).
   PubMed Web of Science ®Google Scholar
• Feld JJ , HoofnagleJH. Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature436 , 967–972 (2005).
   PubMed Web of Science ®Google Scholar
• Sen GC . Viruses and interferons. Annu. Rev. Microbiol.55 , 255–281 (2001).
   PubMed Web of Science ®Google Scholar
• Tilg H . New insights into the mechanisms of interferon alfa: an immunoregulatory and anti-inflammatory cytokine. Gastroenterology112 , 1017–1021 (1997).
   PubMed Web of Science ®Google Scholar
• Lau JY , TamRC, LiangTJ, HongZ. Mechanism of action of ribavirin in the combination treatment of chronic HCV infection. Hepatology35 , 1002–1009 (2002).
   PubMed Web of Science ®Google Scholar
• Maag D , CastroC, HongZ, CameronCE. Hepatitis C virus RNA-dependent RNA polymerase (NS5B) as a mediator of the antiviral activity of ribavirin. J. Biol. Chem.276 , 46094–46098 (2001).
   PubMed Web of Science ®Google Scholar
• Crotty S , MaagD, ArnoldJJ et al. The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen. Nat. Med. 6 , 1375–1379 (2000).
   PubMed Web of Science ®Google Scholar
• Fried MW , ShiffmanML, ReddyKR et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med. 347 , 975–982 (2002).
   PubMed Web of Science ®Google Scholar
• Manns MP , McHutchisonJG, GordonSC et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358 , 958–965 (2001).
   PubMed Web of Science ®Google Scholar
• Reiberger T , RutterK, FerlitschA et al. Portal pressure predicts outcome and safety of antiviral therapy in cirrhotic patients with hepatitis C virus infection. Clin. Gastroenterol. Hepatol. 9 , 602–608.e1 (2011).
   PubMed Web of Science ®Google Scholar
• Poynard T , ColomboM, BruixJ et al. Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy. Gastroenterology 136 , 1618–1628.e2 (2009).
   PubMed Web of Science ®Google Scholar
• Jensen DM , MarcellinP, FreilichB et al. Re-treatment of patients with chronic hepatitis C who do not respond to peginterferon-alpha2b: a randomized trial. Ann. Intern. Med. 150 , 528–540 (2009).
   PubMed Web of Science ®Google Scholar
• Pawlotsky JM , ChevaliezS, McHutchisonJG. The hepatitis C virus life cycle as a target for new antiviral therapies. Gastroenterology132 , 1979–1998 (2007).
   PubMed Web of Science ®Google Scholar
• Manns MP , FosterGR, RockstrohJK, ZeuzemS, ZoulimF, HoughtonM. The way forward in HCV treatment – finding the right path. Nat. Rev. Drug Discov.6 , 991–1000 (2007).
   PubMed Web of Science ®Google Scholar
• Lin K , PerniRB, KwongAD, LinC. VX-950, a novel hepatitis C virus (HCV) NS3–4A protease inhibitor, exhibits potent antiviral activities in HCv replicon cells. Antimicrob. Agents Chemother.50 , 1813–1822 (2006).
   PubMed Web of Science ®Google Scholar
• McHutchison JG , EversonGT, GordonSC et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N. Engl. J. Med. 360 , 1827–1838 (2009).
   PubMed Web of Science ®Google Scholar
• Hezode C , ForestierN, DusheikoG et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N. Engl. J. Med. 360 , 1839–1850 (2009).
   PubMed Web of Science ®Google Scholar
• McHutchison JG , MannsMP, MuirAJ et al. Telaprevir for previously treated chronic HCV infection. N. Engl. J. Med. 362 , 1292–1303 (2010).
   PubMed Web of Science ®Google Scholar
• Jacobson IM , McHutchisonJG, DusheikoG et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N. Engl. J. Med. 364 , 2405–2416 (2011).
   PubMed Web of Science ®Google Scholar
• Zeuzem S , AndreoneP, PolS et al. Telaprevir for retreatment of HCV infection. N. Engl. J. Med. 364 , 2417–2428 (2011).
   PubMed Web of Science ®Google Scholar
• Bacon BR , GordonSC, LawitzE et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N. Engl. J. Med. 364 , 1207–1217 (2011).
   PubMed Web of Science ®Google Scholar
• Kwo PY , LawitzEJ, McConeJ et al. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre Phase 2 trial. Lancet 376 , 705–716 (2011).
   Web of Science ®Google Scholar
• Poordad F , McConeJ Jr, Bacon BR et al. Boceprevir for untreated chronic HCV genotype 1 infection. N. Engl. J. Med.364 , 1195–1206 (2011).
   PubMed Web of Science ®Google Scholar
• Pawlotsky JM . Treatment failure and resistance with direct-acting antiviral drugs against hepatitis C virus. Hepatology53 , 1742–1751 (2011).
   PubMed Web of Science ®Google Scholar

Website

• The New England Journal of Medicine. Supplementary appendix for Zeuzem S et al.10.1056/NEJMoa1013086/suppl_file/nejmoa1013086_appendix.pdf">
   Google Scholar